See Selank dosage trends, reconstitution volumes, and vial size patterns from anonymized WPA peptide calculator sessions.
Selank is a synthetic analog of the immunomodulatory peptide tuftsin, studied for its anxiolytic and nootropic effects with a low side-effect profile. This data shows the dose amounts, vial sizes, and diluent volumes researchers most commonly select in the WPA calculator when preparing Selank for subcutaneous or intranasal administration.
Selank is a synthetic heptapeptide engineered at the same Russian institute and by the same Ashmarin/Myasoedov-era research network that produced Semax — but the molecular starting point is different. Selank is a stabilized analog of tuftsin, the L-Thr-L-Lys-L-Pro-L-Arg tetrapeptide fragment of the IgG heavy chain that Najjar and Nishioka isolated in the 1970s and characterized as an immunomodulator and central anxiolytic. The Selank structure adds a Pro-Gly-Pro tail to the tuftsin core — the same enzymatic-stability strategy used in Semax — and the molecule is formally classified in the Russian Federation as an anxiolytic with no benzodiazepine-class binding. The clinical work in Russia, led by the group around Sergei Seredenin and Tatyana Kozlovskaya, established Selank at intranasal doses of 300-900mcg/day for generalized anxiety and adjustment disorders.
Selank is an anxiolytic research peptide most often sourced for anxiety, stress, and focus protocols, and used intranasally or subcutaneously. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.
Selank modulates expression of GABA-A receptor subunits and influences serotonin and dopamine turnover in the limbic system, producing anxiolytic effects without the sedation, withdrawal, or motor impairment associated with classical benzodiazepines. It also exhibits enkephalinase-inhibition and mild immunomodulatory activity inherited from the tuftsin parent.
Russian clinical trials have evaluated Selank in generalized anxiety disorder and adjustment disorders, reporting anxiolytic efficacy comparable to medazepam without sedation. Outside Russia, the molecule remains a research peptide; no Western Phase 2/3 trials have been published.
Selank has a reported half-life of ~30 min, and the dose intervals researchers model most often fall around twice daily (intranasal). Very short plasma half-life. Selank works as discrete pulses rather than building to a steady level — frequency and timing matter more than total daily dose. It is catalogued under Memory Peptides on WPA.
5,497 Selank reconstitution calculations have been logged by the WPA community. The most common dose entered is 500mcg (1,185 calculations). The median dose across all sessions is 300mcg. The most common bacteriostatic water volume is 2mL. The most popular vial size is 10mg (3,994 sessions). The most common dosing frequency is daily (7x/week) (627 logged protocols), followed by once weekly (180).
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.